Months after Novartis buyout, the old Vedere Bio team is back at it with a new pipeline and a fresh $77M
What do you do when Novartis plunks down $150 million to buy your startup before you even hit the clinic? If you’re Cyrus Mozayeni, you start a new one.
On Tuesday, Mozayeni pulled the curtain on a hefty $77 million Series A round to get the ball rolling at Vedere Bio II — an ocular gene therapy company launched by the same leadership and research team from the first Vedere. After handing their lead program to Novartis in 2020, Mozayeni’s team is now regrouping around a different preclinical pipeline which, like the first, is based on tech from the UC Berkeley labs of Ehud Isacoff and John Flannery and UPenn.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 117,700+ biopharma pros reading Endpoints daily — and it's free.